USFDA Classifies Cipla Partner Pharmathen's Greek Facility as Official Action Indicated

Cipla has informed that the US Food and Drug Administration (USFDA) has classified the inspection of its supply partner Pharmathen International SA’s manufacturing facility in Rodopi, Greece, as Official Action Indicated (OAI).

In a regulator filing, the company stated the update was in continuation of previous intimations dated January 7 and January 14 The filing was submitted on Saturday.

According to the document, the US regulator evaluated the facility for compliance with current Good Manufacturing Practices (cGMP). Pharmathen International SA operates as the supply partner for Lanreotide Injection to Cipla USA Inc, a wholly owned subsidiary of the Mumbai-headquartered drugmaker.